Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Strickler on the Rationale of Examining Tucatinib with Trastuzumab in HER2+ CRC

July 25th 2022

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Treatment Options after Disease Progression in Metastatic Colorectal Cancer

July 22nd 2022

Andrea Cercek, MD, explains the potential treatment options for metastatic colorectal cancer after disease progression.

Individualizing Therapy in HER2+ Metastatic Colorectal Cancer

July 22nd 2022

Dr Jaclyn Hechtman presents the profile of a patient with HER2+ metastatic colorectal cancer and has a conversation with Dr Andrea Cercek on how to personalize frontline therapy selection in each patient.

The Future of Molecular Testing in Colorectal Cancer

July 13th 2022

A look at how the molecular testing landscape in colorectal cancer is evolving.

Challenges and Barriers to Colorectal Cancer Molecular Testing

July 13th 2022

Drs Hechtman and Cercek discuss how practice setting affects molecular testing options and the barriers patients face in receiving testing.

Dr. Ross on the Rise of Colon and Rectal Cancer in Young Patients

July 12th 2022

Howard M. Ross, MD, discusses the increase in colon and rectal cancer in young patients.

Dr. Hays on Treatment Options in HER2-Positive CRC

July 11th 2022

John L. Hays, MD, PhD, discusses expanding treatment options for HER2-positive colorectal cancer.

Short Course of Oxaliplatin/Fluoropyrimidine Noninferior for DFS, Neuropathy in High-Risk CRC

July 11th 2022

A 3-month course of oxaliplatin produced disease-free survival noninferior to a 6-month course in patients with high-risk stage II and III colorectal cancer.

Nivolumab Plus Ipilimumab Displays Durable Benefit in MSI-H/dMMR mCRC

July 8th 2022

Nivolumab alone or in combination with ipilimumab continued to demonstrate sustained clinical benefit as second- and first-line therapy, respectively, in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Dr. Hays on the Importance of Genetic Testing in Colorectal Cancer

July 8th 2022

John L. Hays, MD, PhD, discusses the importance of genetic testing in colorectal cancer.

Neoadjuvant Nivolumab Plus Ipilimumab Elicits 100% Response Rate in dMMR Colon Cancer

July 8th 2022

The combination of nivolumab and ipilimumab generated a 100% response rate in patients with mismatch repair–deficient colon cancer and a 29% response rate in patients with MMR-proficient disease.

Predictive ctDNA Testing Opens the Door for Increasingly Personalized Care in Colon Cancer

July 7th 2022

Ben Ho Park, MD, PhD, summarizes exciting data regarding circulating tumor DNA testing, including its ability to determine the benefits of adjuvant chemotherapy, its successful preliminary use in detecting cancer prior to recurrence, and how it may help guide future therapies.

Nivolumab Plus FOLFOXIRI/Bevacizumab Elicits Promising Responses in RAS/BRAF-Mutated mCRC

July 7th 2022

The addition of nivolumab to FOLFOXIRI and bevacizumab resulted in encouraging responses when used as frontline treatment in patients with advanced or metastatic colorectal cancer harboring RAS or BRAF mutations, irrespective of microsatellite status.

Detecting HER2 Amplification in Colorectal Cancer

July 6th 2022

Experts describe which patients should be screened for HER2 amplification in colorectal cancer and how best to detect it.

Molecular Testing Options in Colorectal Cancer

July 6th 2022

A pathologist explains how she chooses between a variety of molecular testing technology options in colorectal cancer.

Tucatinib Plus Trastuzumab Induces Durable Tumor Response in HER2+ mCRC

July 2nd 2022

Patients with previously treated metastatic HER2-positive colorectal cancer experienced clinically meaningful and durable responses to treatment with tucatinib plus trastuzumab, according to data from the phase 2 MOUNTAINEER trial.

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

June 29th 2022

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

June 29th 2022

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

Colon Microbes Provide Clues to Favorable Treatment Options in a Subset of Colon Cancer Patients

June 16th 2022

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey’s only National Cancer Institute-Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable tumors.

Overview of Molecular Testing in Colorectal Cancer

June 15th 2022

Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.